

---

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For the Month of January, 2008

Commission File Number 1-32001

**Lorus Therapeutics Inc.**

---

(Translation of registrant's name into English)

**2 Meridian Road, Toronto, Ontario M9W 4Z7**

---

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-\_\_\_\_\_.

---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: January 8, 2008

By: /s/ "Elizabeth Williams"

Elizabeth Williams  
Director of Finance

---

**EXHIBIT INDEX**

99.1 Lorus Therapeutics Inc. - News Release Dated January 8, 2008

News release via Canada NewsWire, Toronto 416-863-9350

Attention Business/Financial Editors:

**Lorus Therapeutics reports second quarter results for fiscal year 2008**

TORONTO, Jan. 8 /CNW/ - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three months ended November 30, 2007. Unless specified otherwise, all amounts are in Canadian dollars.

FINANCIAL RESULTS

Our loss from operations for the three months ended November 30, 2007 of \$3.0 million (\$0.01 per share) was approximately equal to the net loss of \$3.1 million (\$0.01 per share) during the same period in fiscal 2007. For the six months ended November 30, 2007 our loss from operations, excluding the gain associated with the Arrangement (as discussed below), decreased by 12% to \$5.1 million from \$5.9 million in the same period last year.

On close of the Arrangement, in July 2007, the Company realized a gain on the sale of the shares of Old Lorus in the amount of \$6.3 million resulting in net income for the six month period of \$1.2 million (\$0.01 per share).

Research and development expenses in the three months ended November 30, 2007 increased to \$1.2 million from \$1.1 million in the same period last year. During the six months ended November 30, 2007 research and development costs decreased to \$2.0 million from \$2.4 million in the same period last year. In the three and six month periods ended November 30, 2007, R&D expenditures increased by \$387 thousand and \$231 thousand, respectively, offset by a decrease in amortization expense related to intangible assets of \$262 thousand and \$655 thousand, respectively, over the same periods in the previous year. These increases are primarily due to increased research and testing costs in fiscal 2008 associated with the advancement of the Company's small molecule program and clinical development costs. These increased costs are partially offset by lower manufacturing and compliance/regulation costs in the current year.

We utilized cash of \$4.9 million in our operating activities in six-month period ended November 30, 2007 compared with \$4.4 million during the same period in fiscal 2007 reflecting a reduction in payables. At November 30, 2007 we had cash and cash equivalents and marketable securities of \$14.8 million compared to \$12.4 million at May 31, 2007.

General and administrative expenses totaled \$1.1 million in the three-month period ended November 30, 2007 compared to \$1.4 million in same period last year. For the six month period ended November 30, 2007, general and administrative expense was \$1.8 million compared with \$2.2 million in the same period last year. The decrease in general and administrative costs is the result of staff reductions, and a continued focus on lowering costs in all areas of the business. In the second quarter of fiscal 2007, the company incurred costs related to the mutual separation agreement between the Company and the then President and CEO. Such costs were not incurred in the current period.

Interest income totaled \$175 thousand in the three-month period ended November 30, 2007 compared to \$158 thousand in the same period last year and \$315 thousand for the six month period ended November 30, 2007 and \$225 thousand for the comparable period last year. The overall increase in interest income in the current period is due to higher average cash and marketable securities balances and interest rates in the current three and six month periods compared to the same periods in fiscal 2007. Higher average cash and marketable securities balances were primarily a function of the funds received as part of the August 2006 private placements and the completion of the Arrangement in July 2007.

<<

Lorus Therapeutics Inc.  
Interim Consolidated Statements of Loss and Deficit  
(unaudited)

(amounts in 000's except for per common share data) (Canadian dollars)	Three months ended Nov. 30, 2007	Three months ended Nov. 30, 2006	Six months ended Nov. 30, 2007	Six months ended Nov. 30, 2006
REVENUE	\$ 1	\$ 23	\$ 27	\$ 30
EXPENSES				
Cost of sales	-	3	1	6

Research and development	1,247	1,122	2,029	2,453
General and administrative	1,103	1,407	1,839	2,195
Stock-based compensation (note 4)	209	150	312	263
Depreciation and amortization of fixed assets	80	100	159	200
-----				
Operating expenses	2,639	2,782	4,340	5,117
Interest expense on convertible debentures	271	262	541	527
Accretion in carrying value of convertible debentures	273	227	539	446
Amortization of deferred financing charges	34	27	66	52
Interest income	(175)	(158)	(315)	(225)
-----				
Loss from operation for the period	3,041	3,117	5,144	5,887
-----				
Gain on sale of shares (note 1)	(216)	-	(6,310)	-
-----				
Net loss/(earnings) and other comprehensive income for the period	2,825	3,117	(1,166)	5,887
-----				
Basic loss (earnings) per share	\$ 0.01	\$ 0.01	\$ (0.01)	\$ 0.03
Diluted loss (earnings) per share	n/a	n/a	\$ (0.01)	n/a
-----				
Weighted average number of common shares outstanding used in the calculation of				
Basic (earnings) loss per share	214,351	209,992	213,704	198,261
Diluted (earnings) loss per share	n/a	n/a	227,266	n/a
-----				

>>

Note re the financial statement information above:

On July 10, 2007 (the "Arrangement Date"), the Company completed a plan of arrangement and corporate reorganization with 4325231 Canada Inc., formerly Lorus Therapeutics Inc., ("Old Lorus"), 6707157 Canada Inc. and Pinnacle International Lands Inc (the "Arrangement"). As a result of the plan of

arrangement and reorganization, among other things, each common share of Old Lorus was exchanged for one common share of the Company and the assets (excluding certain future tax assets and related valuation allowance) and liabilities of Old Lorus were transferred to the Company and/or its subsidiaries. The Company continued the business of Old Lorus after the Arrangement Date with the same officers and employees and continued to be governed by the same Board of Directors as Old Lorus prior to the Arrangement Date. Therefore, the Company's operations have been accounted for on a continuity of interest basis and accordingly, the consolidated financial statement information above reflect that of the Company as if it had always carried on the business formerly carried on by Old Lorus.

#### About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

#### Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through its website at [www.lorusthera.com](http://www.lorusthera.com). For Lorus' regulatory filings on SEDAR, please go to [www.Sedar.com](http://www.Sedar.com). For SEDAR filings prior to July 10, 2007 you will find these under the company profile for Global Summit Real Estate Inc. (Old Lorus).

%SEDAR: 00025614EF            %CIK: 0000882361

/For further information: Lorus Therapeutics Inc., Dr. Saeid Babaei,  
(416) 798-1200 ext. 490, [ir\(at\)lorusthera.com](mailto:ir(at)lorusthera.com)/  
(LOR. LRP)

CO: Lorus Therapeutics Inc.

CNW 09:25e 08-JAN-08